Amyotrophic Lateral Sclerosis

Avicena completes patient enrollment for ALS-08 phase II clinical trial

Published in Drug Week, November 17th, 2006

Avicena Group, Inc., (AVGO) announced that patient enrollment for the first stage of its phase II ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig disease) clinical trial has been completed by the trial's lead investigator, Paul H. Gordon, MD, of the Eleanor and Lou Gehrig MDA/ALS Research Center at Columbia University in New York.

In this trial, investigators will assess the efficacy, safety and tolerability of Avicena's proprietary ALS-08 drug candidate in separate combinations with minocycline and celecoxib (a COX-2 inhibitor).

"Completion of patient enrollment for this stage is an important step in the advancement of our clinical drug...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2006-11-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry